Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
TKMR's Cash to Debt is ranked higher than
92% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. TKMR: No Debt )
TKMR' s 10-Year Cash to Debt Range
Min: 178.64   Max: No Debt
Current: No Debt

Equity to Asset 0.76
TKMR's Equity to Asset is ranked higher than
79% of the 937 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. TKMR: 0.76 )
TKMR' s 10-Year Equity to Asset Range
Min: 0.03   Max: 0.9
Current: 0.76

0.03
0.9
Interest Coverage No Debt
TKMR's Interest Coverage is ranked higher than
70% of the 582 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. TKMR: No Debt )
TKMR' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 4.13
M-Score: -99999999.99
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -136.89
TKMR's Operating margin (%) is ranked higher than
69% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. TKMR: -136.89 )
TKMR' s 10-Year Operating margin (%) Range
Min: -1268.16   Max: 16.57
Current: -136.89

-1268.16
16.57
Net-margin (%) -197.06
TKMR's Net-margin (%) is ranked higher than
66% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. TKMR: -197.06 )
TKMR' s 10-Year Net-margin (%) Range
Min: -1247.29   Max: 211.18
Current: -197.06

-1247.29
211.18
ROE (%) -45.12
TKMR's ROE (%) is ranked higher than
71% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. TKMR: -45.12 )
TKMR' s 10-Year ROE (%) Range
Min: -155.03   Max: 129.35
Current: -45.12

-155.03
129.35
ROA (%) -34.91
TKMR's ROA (%) is ranked higher than
70% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. TKMR: -34.91 )
TKMR' s 10-Year ROA (%) Range
Min: -59.79   Max: 146.65
Current: -34.91

-59.79
146.65
ROC (Joel Greenblatt) (%) -1652.40
TKMR's ROC (Joel Greenblatt) (%) is ranked higher than
65% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. TKMR: -1652.40 )
TKMR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -923.73   Max: 249.49
Current: -1652.4

-923.73
249.49
Revenue Growth (3Y)(%) -19.60
TKMR's Revenue Growth (3Y)(%) is ranked higher than
68% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. TKMR: -19.60 )
TKMR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -29.8   Max: 101.2
Current: -19.6

-29.8
101.2
EBITDA Growth (3Y)(%) -10.60
TKMR's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 714 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. TKMR: -10.60 )
TKMR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -61.6   Max: 40.6
Current: -10.6

-61.6
40.6
EPS Growth (3Y)(%) -6.80
TKMR's EPS Growth (3Y)(%) is ranked higher than
76% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. TKMR: -6.80 )
TKMR' s 10-Year EPS Growth (3Y)(%) Range
Min: -50.4   Max: 30.8
Current: -6.8

-50.4
30.8
» TKMR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

TKMR Guru Trades in Q2 2013

Jean-Marie Eveillard Sold Out
» More
Q1 2014

TKMR Guru Trades in Q1 2014

Steven Cohen 46,283 sh (New)
Jim Simons 25,000 sh (New)
» More
Q2 2014

TKMR Guru Trades in Q2 2014

Jim Simons 150,200 sh (+500.8%)
» More
Q3 2014

TKMR Guru Trades in Q3 2014

Paul Tudor Jones 100,000 sh (New)
Jim Simons 22,900 sh (-84.75%)
» More
» Details

Insider Trades

Latest Guru Trades with TKMR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-06-30 Sold Out $4.28 - $5.05 $ 13.32181%0
Jean-Marie Eveillard 2013-03-31 New Buy$4.35 - $5.44 $ 13.32182%25000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.20
TKMR's P/B is ranked higher than
83% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. TKMR: 3.20 )
TKMR' s 10-Year P/B Range
Min: 0.32   Max: 262.5
Current: 3.2

0.32
262.5
P/S 15.00
TKMR's P/S is ranked higher than
78% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. TKMR: 15.00 )
TKMR' s 10-Year P/S Range
Min: 0.74   Max: 32.98
Current: 15

0.74
32.98
EV-to-EBIT -8.18
TKMR's EV-to-EBIT is ranked higher than
52% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. TKMR: -8.18 )
TKMR' s 10-Year EV-to-EBIT Range
Min: -29.4   Max: 91.9
Current: -8.18

-29.4
91.9
Current Ratio 5.73
TKMR's Current Ratio is ranked higher than
77% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. TKMR: 5.73 )
TKMR' s 10-Year Current Ratio Range
Min: 0.98   Max: 7.2
Current: 5.73

0.98
7.2
Quick Ratio 5.73
TKMR's Quick Ratio is ranked higher than
78% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. TKMR: 5.73 )
TKMR' s 10-Year Quick Ratio Range
Min: 0.98   Max: 7.2
Current: 5.73

0.98
7.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.87
TKMR's Price/Net Cash is ranked higher than
92% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 53.79 vs. TKMR: 3.87 )
TKMR' s 10-Year Price/Net Cash Range
Min: 0.71   Max: 38.5
Current: 3.87

0.71
38.5
Price/Net Current Asset Value 3.79
TKMR's Price/Net Current Asset Value is ranked higher than
92% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 31.40 vs. TKMR: 3.79 )
TKMR' s 10-Year Price/Net Current Asset Value Range
Min: 0.7   Max: 209
Current: 3.79

0.7
209
Price/Tangible Book 3.20
TKMR's Price/Tangible Book is ranked higher than
88% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9.45 vs. TKMR: 3.20 )
TKMR' s 10-Year Price/Tangible Book Range
Min: 0.63   Max: 177.5
Current: 3.2

0.63
177.5
Price/DCF (Projected) 4.92
TKMR's Price/DCF (Projected) is ranked higher than
93% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. TKMR: 4.92 )
TKMR' s 10-Year Price/DCF (Projected) Range
Min: 3.92   Max: 22.47
Current: 4.92

3.92
22.47
Price/Median PS Value 4.46
TKMR's Price/Median PS Value is ranked higher than
69% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. TKMR: 4.46 )
TKMR' s 10-Year Price/Median PS Value Range
Min: 0.28   Max: 6.73
Current: 4.46

0.28
6.73
Earnings Yield (Greenblatt) -12.30
TKMR's Earnings Yield (Greenblatt) is ranked higher than
65% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. TKMR: -12.30 )
TKMR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.1   Max: 99478.9
Current: -12.3

1.1
99478.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:TKM.Canada, I9DN.Germany,
Tekmira Pharmaceuticals Corp was incorporated on October 6, 2005. The Company develops ribonucleic acid interference therapeutic product candidates as well as provides its lipid nanoparticle delivery technology to pharmaceutical partners in the Canada. The Company's internal product development candidates include TKM-PLK1, an oncology product candidate that is in Phase I clinical trials to kill cancer cells; and TKM-Ebola, an antiviral product, which is in Phase I of clinical trials for the treatment of the Zaire species of Ebola virus infection. In addition, the Company has licenses from Alnylam targeting two validated oncology targets, WEE1 and CSN5; and to develop TKM-ALDH2, a systemically delivered RNAi therapeutic that utilizes lipid nanoparticle technology for the treatment of alcohol dependence.
» More Articles for TKMR

Headlines

Articles On GuruFocus.com
Tekmira Pharmaceuticals Gets Mixed Ratings After Ebola Drug Updates Nov 11 2014 
Ebola: Is The Cure Out There? Oct 14 2014 
Ebola Diagnosis in U.S. Raises Pharmaceutical Stock by 20% Oct 01 2014 

More From Other Websites
Tekmira Establishes Manufacturing and Clinical Trial Agreement to Provide TKM-Ebola-Guinea for... Dec 22 2014
TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 22 2014
Tekmira Establishes Manufacturing and Clinical Trial Agreement to Provide TKM-Ebola-Guinea for... Dec 22 2014
Tekmira Receives Clearance to Conduct a Phase I Clinical Study With TKM-HBV Dec 22 2014
8:45 am Tekmira Pharma Receives Clearance to Conduct a Phase I Clinical Study With TKM-HBV Dec 22 2014
Tekmira Receives Clearance to Conduct a Phase I Clinical Study With TKM-HBV Dec 22 2014
TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other... Dec 19 2014
Tekmira Pharmaceuticals Announces Leadership Changes Dec 19 2014
Tekmira Pharmaceuticals Announces Leadership Changes Dec 19 2014
The Ebola Treatment You Haven't Heard Of Dec 19 2014
TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events Nov 28 2014
Tekmira Files Shelf Registration Statement Nov 26 2014
Tekmira Files Shelf Registration Statement Nov 26 2014
Merck, Iowa firm sign Ebola vaccine licensing deal Nov 24 2014
TEKMIRA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events Nov 24 2014
Lightning Round: You're playing with fire Nov 21 2014
Tekmira Provides Key Highlights of Analyst and Investor Day in New York Nov 21 2014
Tekmira Provides Key Highlights of Analyst and Investor Day in New York Nov 21 2014
4 More Biotech Stocks to Buy, With Up to 200% Upside Nov 21 2014
Tekmira Pharmaceuticals (TKMR) Showing Signs Of Perilous Reversal Today Nov 18 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK